BridgeBio Pharma
BBIO
435 hedge funds and large institutions have $14.4B invested in BridgeBio Pharma in 2025 Q4 according to their latest regulatory filings, with 102 funds opening new positions, 154 increasing their positions, 140 reducing their positions, and 50 closing their positions.
451% more call options, than puts
Call options by funds: $894M | Put options by funds: $162M
104% more first-time investments, than exits
New positions opened: 102 | Existing positions closed: 50
64% more funds holding in top 10
Funds holding in top 10: 14 → 23 (+9)
50% more capital invested
Capital invested by funds: $9.62B → $14.4B (+$4.83B)
11% more funds holding
Funds holding: 392 → 435 (+43)
10% more repeat investments, than reductions
Existing positions increased: 154 | Existing positions reduced: 140
1.14% more ownership
Funds ownership: 96.85% → 98% (+1.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$148M |
| 2 |
Janus Henderson Group
London,
|
+$148M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$87.3M |
| 4 |
Allspring Global Investments
Charlotte,
North Carolina
|
+$64.8M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
+$62.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$104M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$100M |
| 3 |
ACM
Aisling Capital Management
New York
|
-$65.6M |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$54.6M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$51.2M |
BBIO Hedge Fund Activity: Q4 2025 in Review
435 of the 8,284 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Pharma (BBIO) for Q4 2025, worth a combined $14.4B — up 50% from $9.62B a quarter earlier.
Buyers outnumbered sellers: 102 funds opened new BBIO positions and 50 closed out — a net gain of 52 holders — while 154 added to existing stakes and 140 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $148M. The largest seller was Viking Global Investors, cutting an estimated $104M.
- 435 institutional investors held BridgeBio Pharma (BBIO) as of Q4 2025, up from 392 in Q3 2025.
- Funds reported $14.4B of BridgeBio Pharma stock for Q4 2025, up 50% quarter-over-quarter.
- 102 funds opened new BridgeBio Pharma positions in Q4 2025 and 50 closed out, a net change of +52 holders.
- The largest BridgeBio Pharma buyer in Q4 2025 was T. Rowe Price Associates, an estimated $148M added.
- The largest BridgeBio Pharma seller in Q4 2025 was Viking Global Investors, an estimated $104M sold.
Based on aggregated 13F filings for Q4 2025.